Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)

Empowering Medicare Patients to Self-Manage Their Type 2 Diabetes Using Continuous Glucose Monitoring (CGM) - Investigational Device Pilot (SMA Investigational Device)

This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels. Subjects will also wear an activity tracker to monitor their activity and observe its effect on their glucose levels. The educational program will involve calls from coaches to check subjects' progress and answer questions.

Inclusion Criteria:

• Be diagnosed with type 2 diabetes
• Be able to read and understand English
• Have access to a telephone
• Have a Medicare Advantage health plan through Senior Dimensions

Exclusion Criteria:

• Pregnant

• Blind

• Deaf

• Receiving chemotherapy or radiation to treat cancer (now or in past 6 months)

• Misusing any drugs (including alcohol, painkillers, hallucinogens, or others)

• Critically ill

• Diagnosed with or experiencing:

  • Kidney disease stages 4 and 5
  • End stage renal disease
  • Severe liver disease
  • Dementia
  • Schizophrenia
  • Bipolar disorder
  • Autism
  • An intellectual or learning disability
  • Arrhythmias other than atrial fibrillation
  • Congestive heart failure

• Has had a:

  • Myocardial infarction within the last 6 months
  • Stroke within the last 6 months
  • Stroke that resulted in significant disability (e.g., unable to write clearly or walk)